Discover How Ginger Got Her Voice Back
Finding a Treatment for Non-Small Cell Lung Cancer
AstraZeneca (AZ) is a global biopharmaceutical company whose innovative medicines are used by millions of patients worldwide. We extended our initial three-year partnership with AZ into 2020, further solidifying our strategic partnership for outsourced, regulated, safety assessment, and development DMPK (drug metabolism and pharmacokinetics).
Between 2013-2015, Charles River performed toxicology studies on AZ's compound, Osimertinib, to meet an accelerated FDA timeline. Our work in preclinical development and clinical support services were vital to ensuring the drug's dosage levels would be safe for patients like Ginger.
Osimertinib is designed to treat patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer who progressed on or after EGFR TKI therapy. It was brought to market in November 2015 and granted Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval status by the FDA – progressing from clinical trials to market in just over two years.
Meet Mila
In 2017, Mila was diagnosed with a particularly rare and fatal disease with no therapy available. See how this little girl has changed the future of drug development.
Mila's Story